ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CVM Cel Sci Corporation New

1.68
0.20 (13.51%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cel Sci Corporation New AMEX:CVM AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 13.51% 1.68 1.73 1.49 1.50 382,304 00:16:47

CEL-SCI CEO Geert Kersten Was a Featured Guest on Fox Business’ Making Money with Charles Payne

18/02/2016 12:45pm

Business Wire


Cel Sci (AMEX:CVM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cel Sci Charts.

CEL-SCI Corporation (NYSE MKT:CVM) announced today that its Chief Executive Officer Geert Kersten was a guest on Fox Business’ Making Money with Charles Payne. The segment, which focused on finding a cure to cancer aired on Wednesday, February 17 between 6:00 and 7:00 p.m. ET. To view the segment, please visit: http://video.foxbusiness.com/v/4761247378001/are-scientists-on-the-cusp-of-finding-a-cure-for-cancer/?#sp=show-clips

About CEL-SCI Corporation

CEL-SCI is a Phase 3 immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. We believe that one must activate the immune system BEFORE radiation and chemotherapy, and even before surgery, to achieve the best results in the greatest number of patients. CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine (Leukocyte Interleukin Injection) for the treatment of head and neck cancer, which accounts for about 6% of cancers globally and a $6 billion market. Almost 700 patients are already enrolled in this study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own 75,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. When fully built out, this facility will have the capacity to supply about $3 billion worth of Multikine annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For CEL-SCI Corporation:Gavin de Windt, 703-506-9460www.cel-sci.com

1 Year Cel Sci Chart

1 Year Cel Sci Chart

1 Month Cel Sci Chart

1 Month Cel Sci Chart

Your Recent History

Delayed Upgrade Clock